# Azithromycin - Ivermectin Mass Drug Administration for Skin Disease

> **NCT02775617** · PHASE4 · COMPLETED · sponsor: **London School of Hygiene and Tropical Medicine** · enrollment: 1291 (actual)

## Conditions studied

- Scabies
- Yaws
- Impetigo

## Interventions

- **DRUG:** Ivermectin
- **DRUG:** Azithromycin
- **DRUG:** Permethrin

## Key facts

- **NCT ID:** NCT02775617
- **Lead sponsor:** London School of Hygiene and Tropical Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2017-08
- **Final completion:** 2018-02-05
- **Target enrollment:** 1291 (ACTUAL)
- **Last updated:** 2019-09-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02775617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02775617, "Azithromycin - Ivermectin Mass Drug Administration for Skin Disease". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02775617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*